Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

2.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.

Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review.

PMID:
16787142
3.

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.

Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D.

Expert Opin Investig Drugs. 2002 Feb;11(2):283-93. Review.

PMID:
11829717
4.

Chemotherapy for hormone-refractory prostate cancer.

Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. Review.

PMID:
17054249
5.

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.

BJU Int. 2007 Jul;100 Suppl 2:60-2. Review. No abstract available.

6.

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).

Mitsogiannis IC, Skolarikos A, Deliveliotis C.

Expert Opin Pharmacother. 2009 Feb;10(3):493-501. doi: 10.1517/14656560802694689 . Review.

PMID:
19191684
7.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
8.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
9.

Bisphosphonates for advanced prostate cancer.

Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006250. Review.

PMID:
17054286
10.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
11.

Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M.

Expert Opin Investig Drugs. 2013 Nov;22(11):1385-400. doi: 10.1517/13543784.2013.824422. Epub 2013 Sep 12. Review.

PMID:
24024652
12.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
13.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
14.

Characterising the castration-resistant prostate cancer population: a systematic review.

Kirby M, Hirst C, Crawford ED.

Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. Review.

PMID:
21995694
15.

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Loriot Y, Massard C, Fizazi K.

Ann Oncol. 2012 May;23(5):1085-94. doi: 10.1093/annonc/mdr573. Epub 2012 Jan 20. Review.

PMID:
22267211
16.

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.

Chung LW, Baseman A, Assikis V, Zhau HE.

J Urol. 2005 Jan;173(1):10-20. Review.

PMID:
15592017
17.

Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer.

Msaouel P, Galeas JN, Boiles AR, Ruiz RR, Koutsilieris M.

Curr Drug Targets. 2016;17(3):276-89. Review.

PMID:
25892311

Supplemental Content

Support Center